Virios therapeutics (nasdaq: viri) advancing potential paradigm shift in fibromyalgia treatment

Armed with near-term catalyst, viri is poised for next growth stagenew york, new york--(newsfile corp. - july 26, 2022) - pcg digital -- development-stage biotechnology company virios therapeutics (nasdaq: viri) is working to advance a new therapeutic approach, one that is focused on addressing a potential root cause of fibromyalgia (fm), a catalyst the company believes is related to activation of previously dormant herpes virus infection.
VIRI Ratings Summary
VIRI Quant Ranking